ENTITY
Eris Lifesciences

Eris Lifesciences (ERIS IN)

36
Analysis
Health CareIndia
Eris Lifesciences Limited manufactures, markets, and sells generic drugs. The Company focuses on cardiology, diabetology, endocrinology, gastroenterology, ENT, orthopedics, pediatrics, and gynecology segments. Eris Lifesciences distributes pharmaceutical drugs throughout India. v
more
Refresh
29 Jan 2020 07:51

EM Pullback Opportunity

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point,...

Logo
406 Views
Share
17 Nov 2018 13:46

Eris Lifesciences - 2QFY19 – Acquisitions Drive Top Line Much Higher, Bottom Line to Follow by FY20E

Eris Lifesciences (ERIS IN) reported lower than expected performance in 2QFY19.  Revenues were 5% lower than our estimates at Rs 2,642 mn. The...

Logo
407 Views
Share
12 Oct 2018 20:22

ERIS Lifesciences – FY18 Annual Report Analysis - Strong Rebound in Cash Flow Likely from FY19E

We reviewed the FY18 Annual Report of Eris Lifesciences (ERIS IN). Eris reported the negative free cash flow of ~Rs 3,148 mn due to business...

Logo
443 Views
Share
21 Aug 2018 15:06

Eris Lifesciences - 1QFY19 – Strides Assimilation on Track

Eris Lifesciences (ERIS IN) reported revenue growth of 35% YoY to Rs 2.5 bn (+18% QoQ), EBITDA growth of 24% YoY to Rs 886 mn (+23% QoQ) and...

Logo
266 Views
Share
31 May 2018 16:38

Eris Lifesciences Ltd - Q4FY18 Beats Expectations, FY19E on Track

Eris Lifesciences Limited (ERIS IN) reported Q4FY18 results recently. Performance Highlights  Eris reported Q4FY18 consolidated revenues at Rs 2.1...

Logo
107 Views
Share
x